NCT Number: NCT02665793
Mechanisms Underlying Peanut Allergic Reactions in TRACE Peanut Study Participants: Extension Study
Food allergy affects up to 10% of the population. The mainstay of management involves dietary avoidance and provision of rescue medication in the event of an accidental reaction. The Integrated approaches to food allergen and allergy management (iFAAM) collaboration is an EU-funded academic/clinical/industry consortium with the aim to improve allergen risk management including food labelling. Much of this work requires the validation of the minimum 'eliciting dose' for the food-allergic population and how this can be translated into risk management.
A number of studies (including iFAAM and the TRACE study - NCT01429896) have assessed the eliciting dose for peanut allergic patients, using food challenges where peanut-allergic individuals are eat incremental doses of peanut under strict medical supervision.
In this extension study, peanut-allergic subjects will have undergone (in a cross-over manner) three double-blind, placebo-controlled food challenges to peanut:
1. incremental doses of peanut in a water-continuous matrix; 2. incremental doses of peanut baked into a cookie biscuit; 3. a single dose of peanut in a water-continuous matrix.
The differences in eliciting dose, symptom pattern and underlying physiological mechanisms will provide essential data on how the presentation and consumption of peanut affects the amount needed to trigger an allergic reaction, to inform industry and food regulators as to how to best protect the food-allergic population.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–45 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Written informed consent.
- Male and female participants in the TRACE study (NCT01429896) who are 18-45 years of age at the time of entry to the TRACE study (Visit 1) and had a positive DBPCFC to peanut at baseline (Visit 1).
Exclusion criteria
- unable to comply with study procedures
Treatment and study plan
Single-dose DBPCFC to peanut flour
OtherSingle-dose DBPCFC to peanut in a water-continuous matrix, at a cumulative dose one dosing level below that individual's threshold (established at the baseline challenge). If no reaction is seen, participants will be given the next dosing level.
Single-dose DBPCFC to peanut butter
OtherSingle-dose DBPCFC to peanut in a water-continuous matrix, at a cumulative dose one dosing level below that individual's threshold (established at the baseline challenge). If no reaction is seen, participants will be given the next dosing level.
Primary outcomes
-
Minimum eliciting dose
Time frame: 2 hours
Minimum eliciting dose of peanut to trigger an objective allergic reaction according to international consensus criteria (PRACTALL))
Secondary outcomes
-
Symptom pattern
Time frame: 12 hours
Symptoms experienced following peanut challenge (defined according to international consensus criteria (PRACTALL) )
Sponsors and collaborators
Lead sponsor
Imperial College London
Other
Collaborators
- Cambridge University Hospitals NHS Foundation Trust
- Food Standards Agency, United Kingdom
- University of Manchester
Registry information
Official study title
Mechanisms Underlying the Change in Threshold or Severity of Peanut-allergic Reactions in TRACE Peanut Study Participants - Extension Study
Acronym: TRACEextension
Important dates
- Study start
- 2016
- Primary completion
- 2017
- Study completion
- 2017
- First posted
- Jan 28, 2016
- Registry last updated
- Oct 22, 2019
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
PK/PD Study of IN-001 Sublingual Spray in Healthy Adults
NCT07210320
Anaphylaxis, Food Allergy
St Louis, Missouri, United States
View Trial DetailsFARE Peanut SLIT and Early Tolerance Induction
NCT02304991
Food Allergy, Food Hypersensitivity
Chapel Hill, North Carolina, United States
View Trial DetailsA Randomized, Double-Blind Placebo-Controlled Peanut Sublingual Immunotherapy Trial
NCT00580606
Food Hypersensitivity, Hypersensitivity
Little Rock, Arkansas, United States
View Trial DetailsPeanut Epicutaneous Phase II Immunotherapy Clinical Trial
NCT01904604
Food Hypersensitivity, Hypersensitivity
Little Rock, Arkansas, United States
View Trial Details